EMPA-REG at 11: A Decade of Evidence, A Lifetime of Impact "The Empagliflozin & Empagliflozin + Linagliptin Legacy across the CKM Axis"

Wednesday, September 30th 2026 - 2:30 PM (IST)

6 days to go

17 doctors attending

Wednesday, September 30th 2026 - 2:30 PM (IST)

Medflix

About this session

Join us for an insightful session marking 11 years of the landmark EMPA-REG journey and its transformative impact on patient care. This session will explore the robust evidence supporting Empagliflozin and the Empagliflozin + Linagliptin combination across the Cardiovascular-Kidney-Metabolic (CKM) axis, highlighting their role in improving glycaemic control, protecting cardiorenal health, and redefining outcomes for people living with type 2 diabetes. Discover how a decade of evidence continues to shape clinical practice and deliver a lifetime of benefits for patients.

Faculty

Dr. Prof Bernard Zinman

World-renowned endocrinologist and Professor of Medicine, University of Toronto. Lead investigator of the landmark EMPA-REG OUTCOME trial that transformed cardio-renal-metabolic management in Type 2 Diabetes. Internationally recognized for his pioneering contributions to diabetes research and care.

Dr. Shashank Joshi

Padma Shri Awardee and one of India’s leading endocrinologists. Former President of RSSDI, API, and the Endocrine Society of India, with extensive contributions to diabetes and metabolic health. Renowned clinician, researcher, and educator with over 800 scientific publications

Other details

Registration

Free

Duration

60 min

Replay

Yes

Certificate

Language

English

Supported by

Explore other sessions

SPAF Masterclass - 2026

25 September 2026 | 2:30 PM (IST)

Post-stroke AF detection in elderly and frail patients: age-stratified bleeding risk and the anticoagulation initiation decision

25 September 2026 | 2:45 PM (IST)